Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06274333
PHASE3

Adding Dexmedetomidine or Tramadol to Paracetamol- An Effort to Attenuate Catheter Related Bladder Discomfort

Sponsor: Al-Azhar University

View on ClinicalTrials.gov

Summary

The insertion of a urinary catheter in a patient undergoing a surgical procedure, especially urinary interventions, may lead to catheter-related bladder discomfort (CRBD) with varying degrees of severity during the postoperative period. Paracetamol is a drug with proven efficacy for the management of mild and moderate postoperative pain. Tramadol is a centrally acting, synthetic opioid analgesic with weak opioid agonist properties. It inhibits the detrusor activity by inhibition of type-1 muscarinic (M1) and type-3 muscarinic (M3) receptors. Dexmedetomidine, a highly selective α2-adrenergic receptor agonist, with analgesic, sedative, anxiolysis, sympatholytic, and sedative properties, is a very useful associated agent for general anesthesia.

Official title: The Effect of Adding Dexmedetomidine or Tramadol to Paracetamol- An Effort to Attenuate Catheter Related Bladder Discomfort: A Randomized, Triple-Blind Clinical Trial

Key Details

Gender

MALE

Age Range

20 Years - 50 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2024-02-28

Completion Date

2026-09-30

Last Updated

2026-01-06

Healthy Volunteers

No

Interventions

DRUG

Dexmedetomidine 0.5 mic/kg

Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg,

DRUG

Tramadol 1mg/kg

Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.

DRUG

Paracetamol 10mg/kg

Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg. Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.

Locations (1)

Neveen Kohaf

Cairo, Cairo Governorate, Egypt